President Donald Trump’s February 2, 2026, Truth Social announcement slashing US reciprocal tariffs on Indian goods from 50% to 18%—whilst simultaneously waiving the 25% penalty on India’s Russian oil purchases—delivered an immediate and dramatic reward to India’s pharmaceutical sector before most Indian markets had even opened for trading. Nifty Pharma surged 2.96% by 9:28 AM […]
President Donald Trump‘s February 2, 2026, Truth Social announcement—reducing US reciprocal tariffs on Indian goods from 25% to 18% whilst simultaneously waiving the 25% penalty on India’s Russian oil purchases following New Delhi‘s purchase halt—sent immediate shockwaves through global financial markets that India’s economy had been waiting to receive. GIFT Nifty surged 800 points within
Trump Just Cut India’s Tariffs by 7 Points—and the Markets Didn’t Wait to Celebrate Read More »
Finance Minister Nirmala Sitharaman’s Union Budget 2026-27, unveiled on February 1, presents a curious paradox in India’s healthcare priorities: a bold ₹10,000 crore Biopharma Shakti scheme championing domestic biologics and biosimilars innovation alongside customs duty waivers on 17 cancer drugs and seven rare disease therapies that could slash monthly treatment costs from ₹70,000-₹95,000—yet an overall
India’s Budget Spent ₹10,000 Crore on Pharma Innovation but Forgot Primary Healthcare Read More »
Last October, India’s pharmaceutical exports to the United States plummeted 23.7 per cent in a single month as tariff uncertainties triggered panic across the sector. By November, exports had rebounded with 9.8 per cent growth. This whiplash recovery encapsulates India’s pharmaceutical sector resilience—the world’s third-largest by volume provisioning 20 per cent of global generics demand—which
India’s $52 Billion Pharma Triumph: Record Exports Despite Global Tariff Wars Read More »
Thirty years ago, India’s pharmaceutical industry faced extinction. The 1995 TRIPS agreement forced product patents on a sector built entirely on reverse-engineering, threatening to obliterate the cost advantages enabling affordable generic production. Today, that same sector exports $30.5 billion annually—a sixteen-fold increase since 2001—commands 20 per cent of global generics supply, and holds 48.7 per
How Pharma Survived Patent Shock: India Inc’s Blueprint for the Tariff Era Read More »
Ninety days. That’s how much time a pharmaceutical manufacturer can now save bringing a generic drug or biosimilar to Indian patients. On 28th January 2026, the Union Health Ministry unveiled sweeping amendments to the New Drugs and Clinical Trials Rules 2019, abolishing test licence requirements and introducing simple online intimation for bioavailability and bioequivalence studies
India Cuts Drug Development Time by 90 Days With Radical Regulatory Reform Read More »
A generic drug manufacturer in Gujarat can now access all 27 European Union markets without paying a single rupee in tariffs. A medical device producer in Maharashtra suddenly faces European competition arriving 15 per cent cheaper than before. Both outcomes stem from the same transformative agreement. The India-EU Free Trade Agreement, sealed on 27th January
India’s $572 Billion Opportunity: Pharma’s Gateway to Europe Opens Wide Read More »
A cancer patient in Mumbai could soon pay 15 per cent less for European biologics. An Indian pharmaceutical manufacturer might capture new European markets worth billions. Yet the same trade agreement enabling both outcomes has sparked fierce debate about whether India‘s generic drug industry—supplying 20 per cent of global generics and keeping essential medicines affordable
Cheaper Cancer Drugs, Threatened Patents: India-EU Trade’s Double Edge for Pharma Read More »
A Black child living in a high-deprivation neighbourhood with severe asthma faces a brutal arithmetic: twice the hospitalisation rate, three times the emergency department visits, and a relentless cascade of oral steroids that stunts growth and weakens bones whilst barely controlling symptoms. For families navigating poverty, inadequate housing, and limited healthcare access, paediatric asthma isn’t
How Biologics Slashed Asthma Hospitalisations by 85% in Disadvantaged Children Read More »
Imagine requiring a life-saving cancer immunotherapy, autoimmune treatment, or obesity medication that demands injecting 5 millilitres of thick, viscous liquid through a needle at home—liquid so concentrated it flows like honey, taking minutes of sustained pressure to deliver whilst you hold perfectly still. This isn’t a hypothetical nightmare; it’s the rapidly approaching reality for millions
The 5.5mL Breakthrough: How Two Giants Solved Biologics’ Injection Problem Read More »
